Triazolam is a benzodiazepine used for short term treatment of insomnia. Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions.
- Mechanism
- Curator reviewed
Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
- Primary indication
- For the short-term treatment of insomnia.Curator reviewed · 2 structured indications
- Formula / weight
- C17H12Cl2N4 · 343.21 g/mol (avg)
- First approval
- Canada, 1996 · United States, 1982
- Code names
- DEA No. 2887 · N05CD05 · U 33030
Resolves to
JOFWLTCLBGQGBO-UHFFFAOYSA-NSMILESCC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12What you can answer from here — as of September 13, 2026
Which drugs share a target with Triazolam, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account